Zevra Therapeutics (ZVRA) announced that its CFO and treasurer, R. LaDuane Clifton, will be stepping down from his position with the company, effective December 31 in order to pursue other professional opportunities. The company has initiated a search to identify its next chief financial officer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strategic Focus on Miplyffa Drives Buy Rating Amid Promising Growth Prospects
- Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth
- Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald
- Zevra Therapeutics price target lowered to $24 from $25 at Canaccord
- Zevra Therapeutics: Strong Q3 Performance and Promising Pipeline Justify Buy Rating